{"id":391659,"date":"2014-05-05T00:00:00","date_gmt":"2014-05-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0514-biopharma-chronic-myelogenous-leukemia-prescribing-decisions-and-payer-landscape-in-a-crowded-and-dynamic\/"},"modified":"2026-04-24T05:28:52","modified_gmt":"2026-04-24T05:28:52","slug":"pforeu0514-biopharma-chronic-myelogenous-leukemia-prescribing-decisions-and-payer-landscape-in-a-crowded-and-dynamic","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0514-biopharma-chronic-myelogenous-leukemia-prescribing-decisions-and-payer-landscape-in-a-crowded-and-dynamic\/","title":{"rendered":"Chronic Myelogenous Leukemia: Prescribing Decisions and Payer Landscape in a Crowded and Dynamic Market | Physician &#038; Payer Forum | EU5 | 2014"},"content":{"rendered":"<p>Tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myelogenous leukemia (CML) over the last decade. However, as 2013-approved second-generation TKIs Bosulif (Pfizer\u2019s bosutinib) and Iclusig (Ariad Pharmaceuticals\u2019 ponatinib) join Glivec (Novartis\u2019s imatinib), Sprycel (Bristol-Myers Squibb\u2019s dasatinib), and Tasigna (Novartis\u2019s nilotinib), treatment decisions are becoming increasingly challenging\u2014especially in later lines of CML therapy\u2014with each TKI agent offering a unique blend of benefits and risks, on top of a premium price tag.<\/p>\n","protected":false},"template":"","class_list":["post-391659","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-myeloid-leukemia","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391659\/revisions"}],"predecessor-version":[{"id":577033,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391659\/revisions\/577033"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}